Since F9H4 does not block CD16a, it promotes NK cell-mediated ADCC and inhibits tumor growth in vivo in the context of co-administration with EGFR antibodies, which served here, in this study, as tumor antigen-targeting antibodies. The gene discussed is FCGR3A; the disease is neoplasm.